Getting It Done
to Improve Lives

Our team combines deep science expertise with an entrepreneurial “get it done” mindset. Our team has worked on Phase 3 trials for cardiometabolic medicines like ertuglifozin, sacubitril/valsartan, ezetimibe, vildagliptin; anti-cancer agents like ixazomib, tucatinib, and tagraxofusp; and new modalities including gene therapy for hemophilia and Duchenne’s Muscular Dystrophy. With our know-how, passion, and sense of urgency, we work every day toward a single goal: to generate definitive human proof-of-concept data and streamline clinical development for assets where we see a clear path to becoming a drug.